Anton Buchner

483 total citations
29 papers, 380 citations indexed

About

Anton Buchner is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Anton Buchner has authored 29 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 14 papers in Genetics and 6 papers in Hematology. Recurrent topics in Anton Buchner's work include Neutropenia and Cancer Infections (20 papers), Blood disorders and treatments (14 papers) and Bacterial Identification and Susceptibility Testing (4 papers). Anton Buchner is often cited by papers focused on Neutropenia and Cancer Infections (20 papers), Blood disorders and treatments (14 papers) and Bacterial Identification and Susceptibility Testing (4 papers). Anton Buchner collaborates with scholars based in Germany, Russia and Ukraine. Anton Buchner's co-authors include Peter Bias, Igor Bondarenko, Oleg Gladkov, Stefan Laufer, Udo Müller, Constantin Volovăț, Jean‐Yves Reginster, Sergei Tjulandin, Noa Avisar and Steve Barash and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Anton Buchner

29 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anton Buchner Germany 12 230 170 79 56 47 29 380
Dion Chen United States 8 35 0.2× 51 0.3× 30 0.4× 38 0.7× 13 0.3× 9 357
J. Reichen Switzerland 11 173 0.8× 12 0.1× 24 0.3× 51 0.9× 18 0.4× 34 515
Leo Auerbach Austria 8 96 0.4× 104 0.6× 5 0.1× 96 1.7× 5 0.1× 12 371
P. David Sadowitz United States 10 73 0.3× 26 0.2× 11 0.1× 53 0.9× 19 0.4× 20 376
Woo‐Young Kim South Korea 14 217 0.9× 43 0.3× 40 0.5× 67 1.2× 23 0.5× 24 534
Atsuhito Tone Japan 12 34 0.1× 65 0.4× 19 0.2× 6 0.1× 46 1.0× 30 512
Yusuke Hara Japan 11 78 0.3× 29 0.2× 20 0.3× 137 2.4× 6 0.1× 30 383
Anne‐Joy M. de Graan Netherlands 12 282 1.2× 64 0.4× 36 0.5× 37 0.7× 3 0.1× 16 425
Erdogan Batman Netherlands 6 86 0.4× 88 0.5× 26 0.3× 4 0.1× 7 0.1× 8 201
Lakshmi Vasist United States 11 185 0.8× 11 0.1× 15 0.2× 18 0.3× 4 0.1× 17 480

Countries citing papers authored by Anton Buchner

Since Specialization
Citations

This map shows the geographic impact of Anton Buchner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anton Buchner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anton Buchner more than expected).

Fields of papers citing papers by Anton Buchner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anton Buchner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anton Buchner. The network helps show where Anton Buchner may publish in the future.

Co-authorship network of co-authors of Anton Buchner

This figure shows the co-authorship network connecting the top 25 collaborators of Anton Buchner. A scholar is included among the top collaborators of Anton Buchner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anton Buchner. Anton Buchner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Abboud, Camille N., Henry C. Fung, Anton Buchner, et al.. (2018). Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors. Supportive Care in Cancer. 27(7). 2569–2577. 12 indexed citations
3.
Zou, Linglong, et al.. (2018). Immunogenicity Assessment of Tbo-Filgrastim in Cancer Patients Receiving Chemotherapy. Bioanalysis. 10(15). 1221–1228. 1 indexed citations
4.
Volovăț, Constantin, Igor Bondarenko, Oleg Gladkov, et al.. (2016). Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. Supportive Care in Cancer. 24(12). 4913–4920. 7 indexed citations
5.
Белогурова, М. Б., Miklós Garami, Monika Csóka, et al.. (2016). A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma. Cancer Chemotherapy and Pharmacology. 79(1). 155–164. 4 indexed citations
6.
7.
Volovăț, Constantin, Igor Bondarenko, Oleg Gladkov, et al.. (2015). Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. SpringerPlus. 4(1). 316–316. 17 indexed citations
8.
Bondarenko, Igor, Peter Bias, & Anton Buchner. (2015). Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Supportive Care in Cancer. 24(1). 267–273. 13 indexed citations
9.
Buchner, Anton, et al.. (2014). A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Research and Treatment. 148(1). 107–116. 25 indexed citations
10.
Volovăț, Constantin, Oleg Gladkov, Igor Bondarenko, et al.. (2013). Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy. Clinical Breast Cancer. 14(2). 101–108. 19 indexed citations
11.
12.
Volovăț, Constantin, Oleg Gladkov, Igor Bondarenko, et al.. (2012). Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.. Journal of Clinical Oncology. 30(15_suppl). 9125–9125. 4 indexed citations
13.
Essaian, A., et al.. (2012). Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research and Opinion. 28(7). 1101–1110. 8 indexed citations
14.
15.
16.
Köhler, E., et al.. (2010). Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research and Opinion. 26(10). 2393–2402. 9 indexed citations
17.
Tjulandin, Sergei, et al.. (2010). Epoetin Theta in Anaemic Cancer Patients Receiving Platinum‐Based Chemotherapy: A Randomised Controlled Trial. PubMed. 3(3). 45–53. 18 indexed citations
18.
19.
Reginster, Jean‐Yves, Peter Bias, & Anton Buchner. (2002). First clinical results of licofelone (ml3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis. Annals of the Rheumatic Diseases. 61. 14 indexed citations
20.
Buchner, Anton, et al.. (1966). Cancer of the Lip. Oncology. 20(2). 129–144. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dion Chen Breakdown of academic impact, for papers by J. Reichen Breakdown of academic impact, for papers by Leo Auerbach Breakdown of academic impact, for papers by P. David Sadowitz Breakdown of academic impact, for papers by Woo‐Young Kim Breakdown of academic impact, for papers by Atsuhito Tone Breakdown of academic impact, for papers by Yusuke Hara Breakdown of academic impact, for papers by Anne‐Joy M. de Graan Breakdown of academic impact, for papers by Erdogan Batman Breakdown of academic impact, for papers by Lakshmi Vasist
Rankless by CCL
2026